Tiziana was previously notified by Nasdaq on January 29, 2025 that it was not in compliance with the minimum bid-price listing rule (under Rule 5550 (a) (2)) because its common stock failed to meet ...

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, ...

Among them, CD3 is considered to be the primary target. Image Credit: ACROBiosystems CD3 molecules tend to bind to TCR non-covalently to develop a TCR/CD3 receptor complex on the T-cell’s surface.

Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor ...

Nasal anti-CD3 spray reduces traumatic brain injury in mice, a potential breakthrough for TBI treatment. Read now.

The test uses an AI algorithm to accurately assess the number of immune cells known as CD3 inside early-stage bowel cancer tumors. Bowel cancer, also known as colorectal cancer, is found anywhere ...

It contains one Ig-like (immunoglobulin-like) domain and one ITAM domain. CD3E, along with CD3-gamma, CD3-delta, CD3-zeta, and T-cell receptor (TCR) alpha/beta or gamma/delta heterodimers ...

A new study suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI). By studying the effects of the nasal anti-CD3 in a ...

In addition, the association of CD3 with the TCR–peptide–MHC complex transmits the activation signal to intracellular signalling molecules to initiate a signalling cascade in the T cell.